A ‘designer’ manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, have shown to be successful in the development of a vaccine to counter Venezuelan Equine Encephalitis Virus (VEEV), a biothreat agent, and Chikungunya virus, a mosquito-borne illness causing severe outbreaks around the world, according to a study “Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alphavirus Vaccine Development,” published online May 30 in the journal, Vaccine, published by Elsevier, http://www.sciencedirect.com/
Effective vaccines depend upon the human immune system recognizing a biological structure that is similar to that of a disease-causing organism. A manganese-peptide antioxidant complex of Deinococcus, developed by Uniformed Services University of the Health Sciences (USU) pathology professor Dr. Michael J. Daly and his team, has the remarkable property of protecting proteins from ionizing radiation damage but not protecting the genetic material (DNA or RNA) in viruses and bacteria. Using D. radiodurans, listed in the Guinness Book of World Records as “the world’s toughest bacterium” and which can withstand 3,000 times the levels of gamma radiation that human cells can, Daly found that a disease-causing organism (pathogen) can be exposed to gamma radiation in the presence of a Deinococcus Mn complex, and rendered non-replicative (killed) by overwhelming genetic damage, but still maintain the shape of key surface proteins needed to mount a highly protective immune response. This approach was successfully implemented on viruses for the first time by scientists in the USU lab of the late Dr. Radha K. Maheshwari to produce vaccines against VEEV and Chikungunya virus.
This approach offers a simple, rapid, cost effective and potentially universal inactivation strategy that can be applied to any pathogen requiring immediate attention, for example, Ebola and Zika viruses.
“Application of this methodology has the potential to revolutionize all future vaccine development” says Dr. Paridhi Gupta, a scientist in the Maheshwari laboratory, and the study’s co-lead author.
The Latest on: Vaccine development
- Development of a diagnostic compatible BCG vaccine against Bovine tuberculosison November 28, 2019 at 2:22 am
The DIVA cocktail described here is specific and is not affected by vaccination. Although further experiments are needed to confirm protective efficacy and diagnostic efficacy in the bovine host, the ...
- Building a better malaria vaccineon November 27, 2019 at 6:11 am
But in 2019, children in Ghana, Kenya and Malawi began receiving the RTS,S vaccine against malaria as part of a pilot programme. After 30 years in development, RTS,S is the first malaria vaccine shown ...
- First Step Taken Towards Vaccine Development for Pancreatic Canceron November 27, 2019 at 5:43 am
Professor Yaohe Wang from Queen Mary University of London and the Sino-British Research Centre at Zhengzhou University in China, who led the study, said: "Development of a preventive vaccine against ...
- First malaria vaccine rolled out in Africa—despite limited efficacy and nagging safety concernson November 26, 2019 at 12:27 pm
Malaria vaccines in development interfere with many different parts of the parasite’s complex life cycle. Mosquirix targets so-called sporozoites after they are injected by a mosquito and before they ...
- Newly developed personalized vaccine system could delay onset of pancreatic canceron November 26, 2019 at 10:44 am
By injecting these antigens as a vaccine, the immune system can safely learn how to recognize them as foreign objects - and remember this should they be found in the body again. Professor Yaohe Wang ...
via Google News and Bing News